pharmaphorum
OCTOBER 6, 2022
Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8 billion, respectively, five years later.
STAT
NOVEMBER 12, 2024
The medicine, datopotamab deruxtecan, or Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies have been pouring investments into. But full trial data published in September showed Dato-DXd did not outperform standard chemotherapy on overall survival.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 8, 2021
The entire APAC region already accounts for 30% of all global pharma spending, and within these markets national healthcare expenditure is expected to increase threefold to over $2 trillion by 2030. Chemotherapy still accounted for 72.6% million in 2030. of the oncology market in China in 2019, compared to 17.1%
STAT
NOVEMBER 12, 2024
The medicine, Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies are investing in heavily. AstraZeneca, which is partnered with Daiichi Sankyo on the drug, has cited Dato-DXd as one of the products that will help it nearly double revenue to $80 billion by 2030.
pharmaphorum
MARCH 8, 2022
In the study, Trodelvy (sacituzumab govitecan) met its objective of reducing progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment – including endocrine drugs, CDK4/6 inhibitors and two to four lines of chemotherapy. appeared first on.
Roots Analysis
DECEMBER 9, 2021
These therapies can be used as a monotherapy or in combination with other therapeutic modalities, such as chemotherapy, surgery or radiation therapy. The anti-HER2 therapies target the HER2 receptor proteins present on the surface of tumor cells, inhibiting the HER2 receptors from receiving signals in order to terminate the cellular growth.
Roots Analysis
OCTOBER 4, 2023
One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy. during the period 2023-2035.
Expert insights. Personalized for you.
98 
Let's personalize your content